MoonLake ImmunotherapeuticsMLTXNASDAQ

Revenue (LTM)

Net Income (LTM)

$-227M

-91.1% YoY

Free Cash Flow

$-196M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.2B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	0	0	0
Gross Profit	-0	0	0	0	-3
Operating Income	-54	-65↓21.4%	-54↑16.8%	-143↓164.4%	-245↓71.1%
Net Income	-54	-50↑6.8%	-36↑27.9%	-119↓230.3%	-227↓91.1%
EBITDA	-54	-65↓21.0%	-54↑17.2%	-142↓163.6%	-220↓55.1%
EPS Diluted	-1.45	-2.20↓51.7%	-0.73↑66.8%	-1.89↓158.9%	-3.53↓86.8%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	8	40↑391.4%	451↑1042.0%	180↓60.0%	335↑85.4%
Total Current Assets	10	77↑694.0%	514↑572.0%	474↓7.8%	422↓11.1%
Total Assets	10	77↑693.6%	527↑585.2%	478↓9.2%	424↓11.2%
Total Current Liabilities	21	8↓63.6%	10↑30.0%	22↑125.4%	45↑102.4%
Total Liabilities	21	8↓62.1%	13↑61.6%	25↑88.1%	120↑388.8%
Total Equity	-12	49↑519.9%	496↑913.7%	447↓9.9%	304↓31.9%
Total Debt	15	0↓98.1%	4↑1208.6%	3↓23.5%	76↑2575.6%
Net Debt	7	-39↓663.5%	-447↓1040.8%	-178↑60.3%	-259↓45.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-35	-56↓58.9%	-43↑23.5%	-117↓172.5%	-196↓68.1%
Capital Expenditure	-0	-0↑68.4%	-0↓1677.9%	-1↓82.5%	-0↑93.3%
Free Cash Flow	-35	-56↓58.7%	-43↑23.0%	-117↓171.9%	-196↓67.4%
Stock-Based Comp	0	0	7	7↑2.5%	13↑77.1%
Net Change in Cash	7	31↑369.4%	412↑1208.2%	-271↓165.8%	154↑156.9%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance